Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Realising the potential of biosimilars

Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands

Realising the potential of biosimilars ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )

Comment: Supporting a sustainable biosimilar solution

Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands

Comment: Supporting a sustainable biosimilar solution ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )

Comment: Use of biosimilar monoclonal antibodies in the clinic

Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands

Comment: Use of biosimilar monoclonal antibodies in the clinic ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )

Comment: Critical quality attributes of biosimilars

Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands

Comment: Critical quality attributes of biosimilars ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )

Comment: Immunogenicity of biosimilars

Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands

Comment: Immunogenicity of biosimilars ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )

Simplifying molecular subtypes of metastatic gastric cancer

Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain

Simplifying molecular subtypes of metastatic gastric cancer ( Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain )

Quality of life results from pembrolizumab vs chemotherapy in gastric or...

Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain

Quality of life results from pembrolizumab vs chemotherapy in gastric or gastroesophageal junction cancer ( Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain )

TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of...

Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA

TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens or immunotherapy ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )

VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer

Dr Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany

VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer ( Dr Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )

CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration...

Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands

CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer ( Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands )

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer

Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer ( Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain )

IMspire170: New combination treatment for advanced melanoma

Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain

IMspire170: New combination treatment for advanced melanoma ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )

More from ecancer